Ophthotech Stock Price, News & Analysis (NASDAQ:OPHT)

$3.16 0.15 (4.98 %)
(As of 01/24/2018 01:57 AM ET)
Previous Close$3.01
Today's Range$2.97 - $3.20
52-Week Range$2.24 - $4.86
Volume534,300 shs
Average Volume431,260 shs
Market Capitalization$113.88 million
P/E Ratio2.03
Dividend YieldN/A
Beta1.58

About Ophthotech (NASDAQ:OPHT)

Ophthotech logoOphthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy.

Receive OPHT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:OPHT
CUSIPN/A
Phone+1-212-8458200

Debt

Debt-to-Equity RatioN/A
Current Ratio12.88%
Quick Ratio12.88%

Price-To-Earnings

Trailing P/E Ratio2.02564102564103
Forward P/E Ratio1.10
P/E GrowthN/A

Sales & Book Value

Annual Sales$50.91 million
Price / Sales2.24
Cash FlowN/A
Price / CashN/A
Book Value($2.65) per share
Price / Book-1.19

Profitability

Trailing EPS$1.56
Net Income$-193,420,000.00
Net Margins26.69%
Return on Equity-69.40%
Return on Assets24.91%

Miscellaneous

Employees156
Outstanding Shares36,040,000

Ophthotech (NASDAQ:OPHT) Frequently Asked Questions

What is Ophthotech's stock symbol?

Ophthotech trades on the NASDAQ under the ticker symbol "OPHT."

How were Ophthotech's earnings last quarter?

Ophthotech Corp (NASDAQ:OPHT) posted its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported $5.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.38 by $0.87. Ophthotech had a negative return on equity of 69.40% and a net margin of 26.69%. View Ophthotech's Earnings History.

When will Ophthotech make its next earnings announcement?

Ophthotech is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Ophthotech.

Where is Ophthotech's stock going? Where will Ophthotech's stock price be in 2018?

1 analysts have issued 1 year price targets for Ophthotech's stock. Their predictions range from $4.00 to $4.00. On average, they expect Ophthotech's share price to reach $4.00 in the next year. View Analyst Ratings for Ophthotech.

Who are some of Ophthotech's key competitors?

Who are Ophthotech's key executives?

Ophthotech's management team includes the folowing people:

  • David R. Guyer M.D., Executive Chairman of the Board (Age 58)
  • Glenn P. Sblendorio, President, Chief Executive Officer (Age 61)
  • David Francis Carroll, Chief Financial Officer, Senior Vice President, Treasurer (Age 51)
  • Keith Westby, Chief Operating Officer, Senior Vice President (Age 42)
  • Barbara A. Wood Esq., Senior Vice President, General Counsel, Secretary (Age 54)
  • David E. Redlick, Lead Independent Director (Age 67)
  • Jane Pritchett Henderson, Director (Age 51)
  • Axel Bolte, Independent Director (Age 45)
  • Thomas Dyrberg M.D., Independent Director (Age 63)
  • Michael Jay Ross Ph. D., Independent Director (Age 67)

Who owns Ophthotech stock?

Ophthotech's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (0.55%). Company insiders that own Ophthotech stock include A/S Novo, Axel Bolte, Barbara A Wood, David E Redlick, David Francis Carroll, David R Guyer, Glenn Sblendorio, Henric Bjorn Bjarke, Keith Westby and Samir Chandrakant Patel. View Institutional Ownership Trends for Ophthotech.

Who bought Ophthotech stock? Who is buying Ophthotech stock?

Ophthotech's stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Ophthotech.

How do I buy Ophthotech stock?

Shares of Ophthotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ophthotech's stock price today?

One share of Ophthotech stock can currently be purchased for approximately $3.16.

How big of a company is Ophthotech?

Ophthotech has a market capitalization of $113.88 million and generates $50.91 million in revenue each year. The biopharmaceutical company earns $-193,420,000.00 in net income (profit) each year or $1.56 on an earnings per share basis. Ophthotech employs 156 workers across the globe.

How can I contact Ophthotech?

Ophthotech's mailing address is 1 Penn Plz Fl 35, NEW YORK, NY 10119-0002, United States. The biopharmaceutical company can be reached via phone at +1-212-8458200 or via email at [email protected]


MarketBeat Community Rating for Ophthotech (OPHT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Ophthotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ophthotech (NASDAQ:OPHT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$47.33$59.11
Price Target Upside: 43.37% upside43.37% upside1,596.54% upside1,017.41% upside

Ophthotech (NASDAQ:OPHT) Consensus Price Target History

Price Target History for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ:OPHT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017Stifel NicolausReiterated RatingHold$4.00LowView Rating Details
12/13/2016GabelliDowngradeBuy -> HoldN/AView Rating Details
12/13/2016Morgan StanleyDowngradeOverweight -> Equal WeightN/AView Rating Details
12/12/2016Goldman Sachs GroupUpgradeSell -> NeutralN/AView Rating Details
12/12/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
12/12/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
12/12/2016CowenDowngradeOutperform -> Market PerformN/AView Rating Details
12/12/2016CitigroupDowngradeBuy -> NeutralN/AView Rating Details
12/12/2016BarclaysDowngradeOverweight -> Equal WeightN/AView Rating Details
12/12/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$11.00N/AView Rating Details
12/12/2016SunTrust BanksDowngradeBuy -> HoldN/AView Rating Details
12/12/2016Chardan CapitalDowngradeBuy -> Neutral$15.00N/AView Rating Details
(Data available from 1/24/2016 forward)

Earnings

Ophthotech (NASDAQ:OPHT) Earnings History and Estimates Chart

Earnings by Quarter for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ OPHT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018        
11/8/2017Q3 2017$4.38$5.25ViewN/AView Earnings Details
7/26/2017Q2 2017($1.07)($0.62)$1.38 million$1.66 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.31)($1.20)$1.94 million$1.66 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.64)($1.86)ViewN/AView Earnings Details
11/8/2016Q316($1.64)($1.71)$6.20 million$1.67 millionViewListenView Earnings Details
8/3/2016Q216($1.05)($0.85)$18.64 million$28.20 millionViewListenView Earnings Details
5/4/2016Q116($1.33)($1.03)$7.22 million$15.70 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.02)$7.59 million$4.78 millionViewListenView Earnings Details
11/5/2015Q315($0.98)($1.14)$11.31 million$3.40 millionViewN/AView Earnings Details
8/5/2015Q215($1.02)($1.08)$2.77 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.75)$0.22$3.68 million$41.70 millionViewListenView Earnings Details
2/23/2015Q414($0.57)($1.06)$12.36 million$1.68 millionViewN/AView Earnings Details
11/11/2014Q314($0.62)$0.31$8.02 million$39.58 millionViewN/AView Earnings Details
8/6/2014Q214($0.56)($1.57)$4.31 millionViewN/AView Earnings Details
5/13/2014Q1($0.67)($0.64)ViewListenView Earnings Details
2/27/2014($0.50)($0.65)ViewN/AView Earnings Details
11/13/2013Q313($1.00)($10.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ophthotech (NASDAQ:OPHT) Earnings Estimates

Current Year EPS Consensus Estimate: $2.88 EPS
Next Year EPS Consensus Estimate: $-1.99 EPS

Dividends

Dividend History for Ophthotech (NASDAQ:OPHT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ophthotech (NASDAQ OPHT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 62.53%
Insider Trades by Quarter for Ophthotech (NASDAQ:OPHT)
Institutional Ownership by Quarter for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ OPHT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018Barbara A WoodSVPSell602$3.17$1,908.3417,064View SEC Filing  
1/5/2018David R GuyerInsiderSell3,798$3.17$12,039.6642,458View SEC Filing  
1/5/2018Keith WestbyCOOSell317$3.17$1,004.8925,300View SEC Filing  
1/3/2018Keith WestbyCOOSell356$3.24$1,153.4424,956View SEC Filing  
1/2/2018Barbara A WoodSVPSell5,289$3.19$16,871.9120,472View SEC Filing  
1/2/2018David R GuyerInsiderSell16,520$3.19$52,698.8050,494View SEC Filing  
1/2/2018Glenn SblendorioCEOSell8,089$3.19$25,803.9144,584View SEC Filing  
7/5/2017Barbara A WoodSVPSell5,119$2.58$13,207.0213,451View SEC Filing  
7/5/2017David Francis CarrollCFOSell3,284$2.58$8,472.727,500View SEC Filing  
7/5/2017David R GuyerChairmanSell17,678$2.58$45,609.2437,692View SEC Filing  
7/5/2017Glenn SblendorioCEOSell7,828$2.58$20,196.2431,992View SEC Filing  
6/13/2017David E RedlickDirectorSell700$2.52$1,764.001,050View SEC Filing  
4/3/2017Glenn SblendorioCFOSell7,388$3.56$26,301.28View SEC Filing  
1/5/2017David R GuyerCEOSell3,785$4.96$18,773.6010,997View SEC Filing  
1/5/2017Henric Bjorn BjarkeSVPSell316$4.96$1,567.361,700View SEC Filing  
1/5/2017Samir Chandrakant PatelPresidentSell3,844$4.96$19,066.2418,332View SEC Filing  
1/3/2017Barbara A WoodSVPSell675$4.90$3,307.501,375View SEC Filing  
1/3/2017David R GuyerCEOSell3,484$4.90$17,071.608,231View SEC Filing  
1/3/2017Samir Chandrakant PatelPresidentSell2,999$4.90$14,695.1016,406View SEC Filing  
12/23/2016Barbara A. WoodSVPSell746$4.92$3,670.32View SEC Filing  
12/22/2016Glenn SblendorioCFOSell1,079$4.85$5,233.15View SEC Filing  
12/15/2016A/S NovoMajor ShareholderSell3,610,487$4.87$17,583,071.691,405,487View SEC Filing  
11/1/2016David R GuyerCEOSell22,060$35.61$785,556.6024,541View SEC Filing  
10/3/2016David R GuyerCEOSell22,060$44.37$978,802.2024,541View SEC Filing  
9/29/2016Samir Chandrakant PatelPresidentSell20,000$55.17$1,103,400.0024,239View SEC Filing  
8/29/2016Samir Chandrakant PatelPresidentSell20,000$52.80$1,056,000.00View SEC Filing  
8/1/2016David R GuyerCEOSell24,060$64.47$1,551,148.2056,451View SEC Filing  
7/29/2016Samir Chandrakant PatelPresidentSell20,000$64.21$1,284,200.00176,031View SEC Filing  
7/1/2016David R GuyerCEOSell24,060$52.12$1,254,007.2056,451View SEC Filing  
6/30/2016Samir Chandrakant PatelPresidentSell41,846$51.23$2,143,770.58174,992View SEC Filing  
6/3/2016Axel BolteDirectorBuy3,500$56.97$199,395.006,000View SEC Filing  
6/2/2016Glenn SblendorioCFOSell671$57.20$38,381.201,750View SEC Filing  
6/1/2016David R GuyerCEOSell30,060$52.71$1,584,462.6062,451View SEC Filing  
5/31/2016Samir Chandrakant PatelPresidentSell20,000$53.32$1,066,400.00213,377View SEC Filing  
5/24/2016A/S NovoMajor ShareholderSell1,300,000$49.00$63,700,000.003,610,489View SEC Filing  
5/2/2016David R GuyerCEOSell22,060$46.18$1,018,730.8054,451View SEC Filing  
4/29/2016Samir Chandrakant PatelPresidentSell20,000$46.79$935,800.00231,008View SEC Filing  
4/1/2016David R GuyerCEOSell22,060$44.11$973,066.6054,451View SEC Filing  
3/29/2016Samir Chandrakant PatelPresidentSell20,000$41.85$837,000.00248,410View SEC Filing  
3/1/2016David R GuyerCEOSell22,060$45.48$1,003,288.8054,451View SEC Filing  
2/29/2016Samir Chandrakant PatelPresidentSell20,000$45.13$902,600.00263,736View SEC Filing  
1/29/2016Samir Chandrakant PatelPresidentSell20,000$53.59$1,071,800.00260,911View SEC Filing  
1/28/2016David R. GuyerCEOSell18,598$53.63$997,410.7432,391View SEC Filing  
1/11/2016Nicholas GalakatosDirectorSell3,000$65.72$197,160.005,684View SEC Filing  
1/4/2016Barbara A. WoodSVPSell1,000$76.37$76,370.00746View SEC Filing  
12/30/2015David R. GuyerCEOSell18,582$78.82$1,464,633.2429,910View SEC Filing  
12/30/2015Glenn SblendorioDirectorSell2,000$80.00$160,000.00View SEC Filing  
12/29/2015Samir Chandrakant PatelPresidentSell1,184$77.50$91,760.00278,605View SEC Filing  
12/24/2015Samir Chandrakant PatelPresidentSell26,036$77.09$2,007,115.24278,605View SEC Filing  
12/10/2015Nicholas GalakatosDirectorSell3,000$64.44$193,320.007,684View SEC Filing  
12/1/2015Barbara A. WoodSVPSell2,000$63.24$126,480.00View SEC Filing  
11/30/2015David R. GuyerCEOSell18,582$62.49$1,161,189.1829,910View SEC Filing  
11/24/2015Samir Chandrakant PatelPresidentSell27,215$60.27$1,640,248.05278,605View SEC Filing  
11/18/2015Nicholas GalakatosDirectorSell1,500$60.00$90,000.009,684View SEC Filing  
11/5/2015Samir Chandrakant PatelPresidentSell20,687$53.55$1,107,788.85278,605View SEC Filing  
10/21/2015Samir Chandrakant PatelPresidentSell27,215$43.27$1,177,593.05259,292View SEC Filing  
10/16/2015Barbara A. WoodSVPSell2,000$45.00$90,000.00View SEC Filing  
9/29/2015David R. GuyerCEOSell18,582$37.69$700,355.5829,910View SEC Filing  
9/21/2015Samir Chandrakant PatelPresidentSell27,215$46.34$1,261,143.10259,292View SEC Filing  
8/31/2015David R. GuyerCEOSell18,582$44.88$833,960.1629,910View SEC Filing  
8/20/2015Samir Chandrakant PatelPresidentSell27,215$48.75$1,326,731.25259,292View SEC Filing  
7/20/2015Samir Chandrakant PatelPresidentSell27,215$67.87$1,847,082.05View SEC Filing  
7/17/2015Glenn SblendorioDirectorSell3,000$67.33$201,990.00View SEC Filing  
7/1/2015Barbara A WoodSVPSell2,000$51.94$103,880.00View SEC Filing  
6/29/2015David R GuyerCEOSell18,582$51.05$948,611.10View SEC Filing  
6/18/2015Samir Chandrakant PatelPresidentSell12,000$49.78$597,360.00View SEC Filing  
5/28/2015David R GuyerCEOSell18,582$48.62$903,456.84View SEC Filing  
4/29/2015David R GuyerCEOSell18,582$48.45$900,297.90View SEC Filing  
4/17/2015Samir Chandrakant PatelPresidentSell12,000$50.47$605,640.00View SEC Filing  
3/30/2015Axel BolteDirectorBuy500$48.27$24,135.00View SEC Filing  
3/30/2015David R GuyerCEOSell18,582$48.26$896,767.32View SEC Filing  
3/2/2015Barbara A WoodSVPSell2,000$53.26$106,520.00View SEC Filing  
3/2/2015David R GuyerCEOSell18,582$53.22$988,934.04View SEC Filing  
1/2/2015David R GuyerCEOSell15,034$45.34$681,641.56View SEC Filing  
11/13/2014A/S NovoMajor ShareholderSell995,000$40.20$39,999,000.00View SEC Filing  
11/3/2014David R GuyerCEOSell15,034$39.71$597,000.14View SEC Filing  
10/2/2014David R GuyerCEOSell2,807$38.52$108,125.64View SEC Filing  
10/2/2014Samir Chandrakant PatelPresidentSell1,965$38.04$74,748.60View SEC Filing  
10/1/2014David R GuyerCEOSell12,227$37.30$456,067.10View SEC Filing  
10/1/2014Samir Chandrakant PatelPresidentSell17,676$37.28$658,961.28View SEC Filing  
9/4/2014David R GuyerCEOSell1,107$38.58$42,708.06View SEC Filing  
8/1/2014Bruce PeacockCFOSell6,191$37.78$233,895.98View SEC Filing  
8/1/2014David R GuyerCEOSell13,136$37.85$497,197.60View SEC Filing  
8/1/2014Samir Chandrakant PatelPresidentSell18,986$37.80$717,670.80View SEC Filing  
7/1/2014Bruce PeacockCFOSell7,739$41.07$317,840.73View SEC Filing  
7/1/2014David R GuyerCEOSell15,034$41.08$617,596.72View SEC Filing  
7/1/2014Samir Chandrakant PatelPresidentSell18,986$41.08$779,944.88View SEC Filing  
6/16/2014Nicholas GalakatosDirectorSell144,976$44.17$6,403,589.92View SEC Filing  
6/11/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell211,680$45.42$9,614,505.60View SEC Filing  
6/4/2014Svlsf Iv, LlcMajor ShareholderSell1,966,935$42.54$83,673,414.90View SEC Filing  
6/3/2014Bruce PeacockCFOSell13,931$40.12$558,911.72View SEC Filing  
6/3/2014Svlsf Iv, LlcMajor ShareholderSell1,865,619$40.65$75,837,412.35View SEC Filing  
6/2/2014David R GuyerCEOSell25,417$39.92$1,014,646.64View SEC Filing  
6/2/2014Samir Chandrakant PatelPresidentSell27,873$39.91$1,112,411.43View SEC Filing  
5/30/2014Svlsf Iv, LlcMajor ShareholderSell931,869$40.99$38,197,310.31View SEC Filing  
5/28/2014Svlsf Iv, LlcMajor ShareholderSell980,127$40.19$39,391,304.13View SEC Filing  
5/23/2014Svlsf Iv, LlcMajor ShareholderSell330,450$38.10$12,590,145.00View SEC Filing  
5/13/2014Hbm Healthcare Investments (Camajor shareholderSell500,000$29.75$14,875,000.003,139,902View SEC Filing  
5/1/2014Bruce PeacockCFOSell4,643$32.43$150,572.49View SEC Filing  
5/1/2014David GuyerCEOSell10,665$33.71$359,517.1511,891View SEC Filing  
5/1/2014Samir Chandrakant PatelPresidentSell14,319$32.45$464,651.55104,472View SEC Filing  
3/24/2014Bruce PeacockCFOSell6,137$34.77$213,383.49View SEC Filing  
3/24/2014David GuyerCEOSell12,027$34.53$415,292.3134,583View SEC Filing  
3/24/2014Samir Chandrakant PatelPresidentSell16,876$34.54$582,897.04135,667View SEC Filing  
2/18/2014Svlsf Iv, Llcmajor shareholderSell2,111,364$29.61$62,517,488.04140,228View SEC Filing  
9/30/2013A/S NovoInsiderBuy455,000$22.00$10,010,000.00View SEC Filing  
9/30/2013Hbm Healthcare Investments (CaMajor ShareholderBuy228,000$22.00$5,016,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ophthotech (NASDAQ OPHT) News Headlines

Source:
DateHeadline
Ophthotech Corp (OPHT) Receives Average Recommendation of "Buy" from BrokeragesOphthotech Corp (OPHT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 5:38 PM
Ophthotech Begins Phase II Zimura Study in Stargardt DiseaseOphthotech Begins Phase II Zimura Study in Stargardt Disease
www.zacks.com - January 17 at 10:10 AM
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of ...Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of ...
www.businesswire.com - January 16 at 4:38 PM
Ophthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for Treatment of STGD1Ophthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for Treatment of STGD1
www.streetinsider.com - January 16 at 4:38 PM
Ophthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for ... - StreetInsider.comOphthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for ... - StreetInsider.com
www.streetinsider.com - January 16 at 10:14 AM
Ophthotech Corp (OPHT) Elects Jane Pritchett Henderson to Board - StreetInsider.comOphthotech Corp (OPHT) Elects Jane Pritchett Henderson to Board - StreetInsider.com
www.streetinsider.com - January 16 at 10:14 AM
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of DirectorsOphthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors
finance.yahoo.com - January 16 at 10:14 AM
Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)
finance.yahoo.com - January 16 at 10:14 AM
Technical Perspectives on Biotech Stocks -- Ophthotech, Trevena, PTC Therapeutics, and Halozyme Therapeutics - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- Ophthotech, Trevena, PTC Therapeutics, and Halozyme Therapeutics - PR Newswire (press release)
www.prnewswire.com - January 10 at 10:21 AM
Ophthotech (OPHT) & Flex Pharma (FLKS) Head-To-Head AnalysisOphthotech (OPHT) & Flex Pharma (FLKS) Head-To-Head Analysis
www.americanbankingnews.com - January 9 at 3:42 PM
Ophthotech Corp (OPHT) Insider Sells $12,039.66 in StockOphthotech Corp (OPHT) Insider Sells $12,039.66 in Stock
www.americanbankingnews.com - January 5 at 6:50 PM
David R. Guyer Sells 16,520 Shares of Ophthotech Corp (OPHT) StockDavid R. Guyer Sells 16,520 Shares of Ophthotech Corp (OPHT) Stock
www.americanbankingnews.com - January 3 at 7:54 PM
Glenn Sblendorio Sells 8,089 Shares of Ophthotech Corp (OPHT) StockGlenn Sblendorio Sells 8,089 Shares of Ophthotech Corp (OPHT) Stock
www.americanbankingnews.com - January 3 at 7:54 PM
Insider Selling: Ophthotech Corp (OPHT) SVP Sells 5,289 Shares of StockInsider Selling: Ophthotech Corp (OPHT) SVP Sells 5,289 Shares of Stock
www.americanbankingnews.com - January 3 at 7:54 PM
Ophthotech Corporation to Present at the 36th Annual J.P. Morgan ... - Business Wire (press release)Ophthotech Corporation to Present at the 36th Annual J.P. Morgan ... - Business Wire (press release)
www.businesswire.com - January 2 at 10:33 PM
Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare ConferenceOphthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 10:07 AM
ValuEngine Downgrades Ophthotech (OPHT) to HoldValuEngine Downgrades Ophthotech (OPHT) to Hold
www.americanbankingnews.com - January 1 at 2:20 PM
Comparing Ophthotech (OPHT) and Its RivalsComparing Ophthotech (OPHT) and Its Rivals
www.americanbankingnews.com - December 28 at 3:21 AM
Ophthotech Corp (OPHT) Receives Average Recommendation of "Buy" from AnalystsOphthotech Corp (OPHT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 26 at 6:46 PM
Critical Review: Ophthotech (OPHT) versus The CompetitionCritical Review: Ophthotech (OPHT) versus The Competition
www.americanbankingnews.com - December 23 at 3:07 AM
Analyzing Ophthotech (OPHT) & Its RivalsAnalyzing Ophthotech (OPHT) & Its Rivals
www.americanbankingnews.com - December 22 at 3:04 AM
Critical Survey: Ophthotech (OPHT) versus Its RivalsCritical Survey: Ophthotech (OPHT) versus Its Rivals
www.americanbankingnews.com - December 20 at 11:22 PM
Ophthotech (OPHT) Up 7.1% Since Earnings Report: Can It Continue? - NasdaqOphthotech (OPHT) Up 7.1% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - December 13 at 4:49 PM
Robbins Arroyo LLP Is Investigating the Officers and Directors of Ophthotech Corporation (OPHT) on Behalf of ... - Business Wire (press release)Robbins Arroyo LLP Is Investigating the Officers and Directors of Ophthotech Corporation (OPHT) on Behalf of ... - Business Wire (press release)
www.businesswire.com - December 13 at 4:49 PM
Graybug Vision Expands Executive Leadership Team with Key HiresGraybug Vision Expands Executive Leadership Team with Key Hires
www.bizjournals.com - December 11 at 10:58 AM
Ophthotech (OPHT) Up 7.1% Since Earnings Report: Can It Continue?Ophthotech (OPHT) Up 7.1% Since Earnings Report: Can It Continue?
finance.yahoo.com - December 11 at 10:58 AM
Ophthotech (OPHT) Upgraded to C by TheStreetOphthotech (OPHT) Upgraded to C by TheStreet
www.americanbankingnews.com - December 2 at 7:42 AM
Critical Review: Ophthotech (OPHT) & Its CompetitorsCritical Review: Ophthotech (OPHT) & Its Competitors
www.americanbankingnews.com - December 2 at 5:36 AM
Ophthotech Corp (OPHT) Receives Average Recommendation of "Hold" from BrokeragesOphthotech Corp (OPHT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 2 at 12:00 AM
Regenerons Stock Falls as Mid-Stage Eye Disease Studies FailRegeneron's Stock Falls as Mid-Stage Eye Disease Studies Fail
www.zacks.com - November 28 at 10:28 AM
Report: Exploring Fundamental Drivers Behind Carters, Southern Copper, ViaSat, Bruker, Freds, andReport: Exploring Fundamental Drivers Behind Carter's, Southern Copper, ViaSat, Bruker, Fred's, and
www.nasdaq.com - November 21 at 9:02 AM
ETFs with exposure to Ophthotech Corp. : November 20, 2017ETFs with exposure to Ophthotech Corp. : November 20, 2017
finance.yahoo.com - November 21 at 9:02 AM
Report: Exploring Fundamental Drivers Behind Carters, Southern Copper, ViaSat, Bruker, Freds, and Ophthotech — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Carter's, Southern Copper, ViaSat, Bruker, Fred's, and Ophthotech — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - November 21 at 9:02 AM
Applied Genetic Technologies Corporation (AGTC) & Ophthotech Corporation (OPHT) Critical ContrastApplied Genetic Technologies Corporation (AGTC) & Ophthotech Corporation (OPHT) Critical Contrast
www.americanbankingnews.com - November 17 at 5:06 PM
Ophthotech (OPHT) Jumps: Stock Rises 11.9% - NasdaqOphthotech (OPHT) Jumps: Stock Rises 11.9% - Nasdaq
www.nasdaq.com - November 15 at 7:09 AM
Ophthotech Corporation (OPHT) Lifted to "Strong-Buy" at Zacks Investment ResearchOphthotech Corporation (OPHT) Lifted to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - November 13 at 11:28 AM
Gabelli Weighs in on Ophthotech Corporations FY2017 Earnings (OPHT)Gabelli Weighs in on Ophthotech Corporation's FY2017 Earnings (OPHT)
www.americanbankingnews.com - November 13 at 2:36 AM
ETFs with exposure to Ophthotech Corp. : November 10, 2017ETFs with exposure to Ophthotech Corp. : November 10, 2017
finance.yahoo.com - November 11 at 1:11 PM
Ophthotechs (OPHT) CEO Glenn Sblendorio on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaOphthotech's (OPHT) CEO Glenn Sblendorio on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 10:28 AM
Ophthotech Reports Third Quarter 2017 Financial and Operating Results - Business Wire (press release)Ophthotech Reports Third Quarter 2017 Financial and Operating Results - Business Wire (press release)
www.businesswire.com - November 9 at 10:28 AM
Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus - NasdaqOphthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus - Nasdaq
www.nasdaq.com - November 9 at 10:28 AM
Ophthotech Corp. to Host Earnings CallOphthotech Corp. to Host Earnings Call
finance.yahoo.com - November 9 at 10:28 AM
Ophthotech Reports Third Quarter 2017 Financial and Operating ResultsOphthotech Reports Third Quarter 2017 Financial and Operating Results
finance.yahoo.com - November 9 at 10:27 AM
Ophthotech posts 3Q profitOphthotech posts 3Q profit
finance.yahoo.com - November 9 at 10:27 AM
Ophthotech Soars After Third-Quarter Results -- Biotech MoversOphthotech Soars After Third-Quarter Results -- Biotech Movers
finance.yahoo.com - November 9 at 10:27 AM
Edited Transcript of OPHT earnings conference call or presentation 8-Nov-17 1:00pm GMTEdited Transcript of OPHT earnings conference call or presentation 8-Nov-17 1:00pm GMT
finance.yahoo.com - November 9 at 10:27 AM
Today’s Research Reports on Stocks to Watch: Ophthotech Corporation and HTG Molecular DiagnosticsToday’s Research Reports on Stocks to Watch: Ophthotech Corporation and HTG Molecular Diagnostics
finance.yahoo.com - November 9 at 10:27 AM
Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in FocusOphthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus
finance.yahoo.com - November 9 at 10:27 AM
Ophthotech Corp. :OPHT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Ophthotech Corp. :OPHT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 10:27 AM
Ophthotech Corporation (OPHT) Releases  Earnings ResultsOphthotech Corporation (OPHT) Releases Earnings Results
www.americanbankingnews.com - November 8 at 3:02 PM

SEC Filings

Ophthotech (NASDAQ:OPHT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ophthotech (NASDAQ:OPHT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ophthotech (NASDAQ OPHT) Stock Chart for Wednesday, January, 24, 2018

Loading chart…

This page was last updated on 1/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.